Julia A. Elvin, MD, PhD, discusses her genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.
In an effort to better group tumors into relevant targetable populations, investigators recently evaluated 4114 ovarian tumor specimens to identify the different molecular changes that can occur within the specimens, according to lead investigator, Julia A. Elvin, MD, PhD.
According to Elvin, who presented the results at the 2017 ASCO Annual Meeting, these samples were analyzed for classes of genomic alternations through a hybrid capture based next-generation sequencing platform of up to 315 genes. Tumor subtypes were separated as high-grade serous (n = 2770), difficult to classify (n = 807), and nonserous (n = 537).
In an interview withTargeted Oncology at ASCO, Elvin, who is vice president and senior associate medical director of Foundation Medicine, discussed this genomic research in ovarian cancer and how it could potentially impact treatment decisions for patients.
TARGETED ONCOLOGY:Can you provide an overview of this research?
Elvin:The study that I performed in conjunction with my collaborators was to look at the largest set of ovarian tumor specimensover 4100 ovarian cancers, peritoneal tumors, and fallopian tube tumors. The way that we do this is that we use comprehensive genomic profiling. This is a hybrid capture based next-generation sequencing platform where we looked at 315 different oncogenes and cancer-related genes and fully sequenced them. We were able to capture all 4 categories of genomic alterations, including mutations, inserting/deletion events, and copy number changes, as well as rearrangements. This is incredibly important to this study because the depth and comprehensiveness of the sequencing approach is required for the next level of observations that we are now able to make.
The first level is identifying mutations in any 1 of these more than 300 genes. Then, the second level is to get almost a global genomic-wide landscape of how well the cell's double-strand repair process workstheir homologous recombination pathway. We know that, in ovarian cancer, a large portion of these tumors have loss of the ability to repair breaks in their DNA. Gynecologic oncologists have been taking advantage of this Achilles heel, but didn’t know why it was working for a long time. Platinum-based chemotherapies actually introduce additional double-strand breaks, and it is partially for this reason that it’s believed that these chemotherapies are so effective in many patients with ovarian cancer.
One of the great things about our technology is that we can observe a signature called "loss of heterozygosity” [LOH]. This is when a cell loses its ability to use homologous recombination, which is the high-fidelity repair pathway for double-stranded breaks. It has to go through a collateral channel that is a low-fidelity way of correcting these errors. As this pathway is used over and over again in the tumor cell, a certain specific type of mutational pattern accumulates that we can observe in our sequencing. We cannot only just observe this, but we can quantitate the amount of the genome that is experiencing this type of LOH effect.
The ARIEL2 and ARIEL3 trials with the PARP inhibitor rucaparib (Rubraca) showed that patients who have homologous recombination deficiency respond to the synthetic lethality of the PARP inhibitors because they block the collateral circulation through other repair pathways. We have both ways to identify patients with this biomarker as well as have some clinical data to show that this is an important way of stratifying patients.
We applied this approach to 4000 mixed ovarian cancers. Generally, the [samples] that come to us are late-stage and often treatment refractory, at that point. We found that 41% of this mixed population of ovarian tumors had either aBRCA1orBRCA2mutation or this observable pattern of LOH. This means that 4 out of 10 patients could potentially benefit from a PARP inhibitor.
People tend to think about platinum sensitivity in this PARP inhibitor approach as it pertains to a certain subset of ovarian cancersthe serous cancers. A lot of the clinical trials are specifically designed to exclude patients that have the less common, but incredibly difficult-to-treat nonserous tumors. It is actually these patients who have the highest unmet clinical need because they do not respond to platinum therapy as readily. We looked specifically at the nonserous patients, and found that 19%—nearly 1 in 5 nonserous patients—had either aBRCAmutation, or this pattern of LOH. So, [there were] not as many as the serous patients, but it was still a reasonable thing to consider for these patients who often run out of options.
The third thing that we did is we asked, “If you decide to triage these patients who have the pattern that might make PARP a good category for them, what about the patients who don't look like great PARP candidates?” Is there something that we can seea pattern that would emerge for these patients—that would allow us to identify additional treatment strategies? By looking at tumor mutation burden and microsatellite instability, we found that between 1% and 5%, depending on the specific cell type, would have a biomarker that would suggest that they may benefit from an immune checkpoint inhibitor approach.
Further beyond that, we found lots of patients who have targetable alterations with small molecule inhibitorsPI3K, mTOR, AKT pathway activity events, MEK pathway activating events, and even a proportion of patients who look like they have HER2-activating events. Taken together, of the patients who don’t have aBRCAmutation and an LOH profile, over 50% of the remaining patients would have something that was potentially targetable in an on-label or clinical trial setting.
The added benefit is, for the patients who are in that 50% who don't have an identifiable next step from their molecular profile, it becomes a lot clearer what the actual options are for them to consider. These may be patients who we should think more about radiation therapy for, or additional lines of chemotherapy, or additional de-bulking surgery. Or, maybe we even start considering some of the other comfort measures or nontargeted therapy clinical trials.
TARGETED ONCOLOGY:How do you envision this changing the landscape of ovarian cancer?
Elvin:I see that these results really have the opportunity to change the landscape of treatment possibilities for patients with ovarian cancer. It is incredibly powerful to think of a time in the future where a patient would come into the doctor’s office knowing the enemy that they were going to face in molecular detail and be able to devise, not just the first step plan of surgery and maybe some adjuvant chemotherapy, but actually have a strategy of what they are going to do when these tumors come back, which most of them do.
To think that well over 50% of these patients have options revealed to them that they wouldn't have considered just based on the tumor pathology is an extraordinary advance.
TARGETED ONCOLOGY:What are the next steps?
Elvin:There is still a lot of work to be done in this area. Most critical is the need for combining clinical data. So, with a data set of this size, this means patient characteristics and clinical treatment outcomes for both conventional chemotherapy and targeted therapy.
One of the limitations that we have is that we know the molecular story, but we are relatively blind to the clinical story in a lot of these cases. That is really what is going to allow us to build upon these findings and identify the most clinically significant characteristics for future direction of care.
TARGETED ONCOLOGY:Are there any other remaining challenges?
Elvin:One of the challenges that remains is that the field is still driven by a site-specific and name-specific classification system for these patients, which limits physicians’ creativity and thus limits a patient’s treatment options.
Elvin JA, He Y, Sun J, et al. Comprehensive genomic profiling (CGP) with loss of heterozygosity (LOH) to identify therapeutically relevant subsets of ovarian cancer (OC).JClin Oncol.2017;35 (suppl; abstr 5512).